CN EN

INSIGHTS

BioDuro-Sundia is proud to highlight the Head of Oncology Dr. Phillip Wang’s insights on the topic of Building New Models for Preclinical In vivo Immuno-Oncology Efficacy Studies and welcome you to explore BioDuro-Sundia Oncology Services.

Click here to learn more about BioDuro-Sundia oncology services.

What is the in vivo pharmacodynamic model’s role in the big picture of new drug research?

The research and development of new drugs must complete a triathlon of drug discovery, preclinical research and clinical trials before benefiting the patients. It is a long and arduous research process. 

Where preclinical research begins, there are four main systematic studies on involved:

Pharmaceutical research of APIs and formulation

Pharmacological efficacy

DMPK

Safety assessment

The latter three studies mentioned require in vivo testing. 

Pharmacodynamics research is to answer the mechanism of drug action to determine the dosage and frequency of drug administration. Finding suitable molecules and cells for in vitro efficacy evaluation while building a symptomatic animal model for in vivo efficacy evaluation is the key in this research phase. 

DMPK research studies the absorption, distribution, metabolism, and excretion properties (ADME) of drugs in animals to guide the form of drug administration in clinical research. Additionally, DMPK helps to determine the frequency and dosage of new drug. 

Safety assessment needs to be evaluated in at least two animal species. The key results of toxic target organ, maximum tolerated dosage and no obvious toxic reaction dosage can provide a basis to determine the starting dosage for the first human trial and to formulate risk prevention and control measures in human clinical trials. For new drugs that require long-term use to treat chronic diseases, it is necessary to conduct toxicological experiments for a longer period of time. These demonstrate that animal models are an indispensable part of preclinical drug development.

What are common challenges in preclinical in vivo immune-oncology efficacy studies?

The establishment and selection of appropriate animal models fully comprehend each aspect of pharmacological efficacy, DMPK and safety assessment

Difficulties arise when trying to establish the model, or when trying to select a model after establishment. Such challenges cause misleading or ineffective clinical results from animal model testing. That is, the clinical transformation falls short.

When it comes to oncology immunotherapy animal models, what technical expertise does BioDuro-Sundia bring to the table?

BioDuro-Sundia animal models for oncology immunotherapy continue to expand; both increasing the number of models and expanding into new types of models. BioDuro-Sundia capabilities in this area of preclinical research is exceptionally systematic and comprehensive. We’ve accumulated vast historical data and indispensable first-hand experiences in pharmacology efficacy. As market demand for pharmacology efficacy grows, so too does BioDuro-Sundia’s strategic investment and efforts to advance the area.

0.151317s
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all